Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oxford BioMedica reshuffles board

This article was originally published in Scrip

Executive Summary

Oxford BioMedica has named Drs Paul Blake and Andrew Heath independent non-executive directors following the retirement of Mark Berninger from the board. Dr Blake is senior vice-president and chief medical officer of Aeterna Zentaris, while Dr Heath was CEO of Protherics from 1997 to 2008. Mr Berninger will step down from Oxford BioMedica, having served as an independent non-executive director since 1999. Separately, the firm has appointed Adam Love senior director of commercial activities and strategic planning; he was previously medical director for Cephalon and Archimedes.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts